My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 181

    1.

    Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes.

    Blüher M, Lübben G, Paschke R.

    Diabetes Care. 2003 Mar;26(3):825-31.PMID: 12610044 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Association of the PRO12ALA polymorphism of the PPAR-gamma2 gene with oxidized low-density lipoprotein and cardiolipin autoantibodies in nondiabetic and type 2 diabetic subjects.

    Niskanen L, Lindi V, Erkkilä A, Sivenius K, Luoma J, Ylä-Herttuala S, Laakso M, Uusitupa MI.

    Metabolism. 2003 Feb;52(2):213-7.PMID: 12601635 [PubMed - indexed for MEDLINE]Related articles

    3.

    Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes.

    Kang ES, Park SY, Kim HJ, Kim CS, Ahn CW, Cha BS, Lim SK, Nam CM, Lee HC.

    Clin Pharmacol Ther. 2005 Aug;78(2):202-8.PMID: 16084854 [PubMed - indexed for MEDLINE]Related articles

    4.

    A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.

    Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S, Hawkins F, Lochnan H, Escobar-Jiménez F, Hardin PA, Konkoy CS, Tan MH.

    Clin Ther. 2003 Apr;25(4):1074-95.PMID: 12809958 [PubMed - indexed for MEDLINE]Related articles

    5.

    Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study.

    Snitker S, Watanabe RM, Ani I, Xiang AH, Marroquin A, Ochoa C, Goico J, Shuldiner AR, Buchanan TA; Troglitazone in Prevention of Diabetes (TRIPOD) study.

    Diabetes Care. 2004 Jun;27(6):1365-8.PMID: 15161789 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

    Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA.

    Diabetologia. 2007 Aug;50(8):1723-31. Epub 2007 May 23.PMID: 17520238 [PubMed - indexed for MEDLINE]Related articles

    7.

    [Association of Pro12Ala variant in peroxisome proliferator-activated receptor-gamma2 gene with type 2 diabetes mellitus]

    Fu M, Chen H, Li X, Li J, Wu B, Cheng L, Cai M, Fu Z.

    Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2002 Jun;19(3):234-8. Chinese. PMID: 12048686 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

    Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

    9.

    Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.

    Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA.

    Clin Ther. 2005 Aug;27(8):1181-95.PMID: 16199244 [PubMed - indexed for MEDLINE]Related articles

    10.

    Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.

    Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M.

    Lancet. 2009 Jul 11;374(9684):126-35. Epub 2009 Jun 8.PMID: 19515415 [PubMed - indexed for MEDLINE]Related articles

    11.

    Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.

    Tan M, Johns D, González Gálvez G, Antúnez O, Fabián G, Flores-Lozano F, Zúñiga Guajardo S, Garza E, Morales H, Konkoy C, Herz M; GLAD Study Group.

    Clin Ther. 2004 May;26(5):680-93.PMID: 15220012 [PubMed - indexed for MEDLINE]Related articles

    12.

    Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitus.

    Wang G, Wang X, Zhang Q, Ma Z.

    Int J Clin Pract. 2007 Apr;61(4):552-7.PMID: 17394430 [PubMed - indexed for MEDLINE]Related articles

    13.

    Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study.

    Herrmann SM, Ringel J, Wang JG, Staessen JA, Brand E; Berlin Diabetes Mellitus (BeDiaM) Study.

    Diabetes. 2002 Aug;51(8):2653-7.PMID: 12145184 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group.

    Clin Ther. 2006 Oct;28(10):1556-68.PMID: 17157112 [PubMed - indexed for MEDLINE]Related articles

    15.

    Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.

    Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Grossman L, Oakley D, Tan M; H6E-MC-GLAT study group.

    Clin Ther. 2005 May;27(5):554-67.PMID: 15978304 [PubMed - indexed for MEDLINE]Related articles

    16.

    Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus.

    Rajagopalan R, Perez A, Ye Z, Khan M, Murray FT.

    Drugs Aging. 2004;21(4):259-71.PMID: 15012171 [PubMed - indexed for MEDLINE]Related articles

    17.

    Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients.

    Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM.

    Diabetes Care. 2002 Feb;25(2):376-80.PMID: 11815513 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial.

    Andrulionytè L, Zacharova J, Chiasson JL, Laakso M; STOP-NIDDM Study Group.

    Diabetologia. 2004 Dec;47(12):2176-84. Epub 2004 Dec 8.PMID: 15592662 [PubMed - indexed for MEDLINE]Related articles

    19.

    Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study.

    Raz I, Stranks S, Filipczak R, Joshi P, Lertoft B, Rastam J, Chow CC, Shaban J.

    Clin Ther. 2005 Sep;27(9):1432-43.PMID: 16291416 [PubMed - indexed for MEDLINE]Related articles

    20.

    Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

    Roberts VL, Stewart J, Issa M, Lake B, Melis R.

    Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity